Table. Patients Characteristics, Lesion Characteristics, and QCA and Restenosis Dataa.
| Variables | TGCV | Control | P value |
|---|---|---|---|
| Patients characteristics | |||
| No. of patients | 7 | 74 | |
| Men | 5 (71) | 58 (78) | .65 |
| Age, mean (SD), y | 66.3 (12.8) | 65.6 (10.6) | .88 |
| Race/ethnicity, Asian | 7 (100) | 74 (100) | >.99 |
| BMI, mean (SD), kg/m2 | 22.9 (3.9) | 24.2 (4.0) | .41 |
| BMIPP wash-out, mean (SD), % | 2.8 (6.0) | 25.9 (10.5) | <.001 |
| Hypertension | 6 (86) | 40 (54) | .13 |
| Dyslipidemia | 6 (86) | 49 (66) | .42 |
| Current smoker | 2 (29) | 25 (34) | >.99 |
| Prior MI | 3 (43) | 9 (12) | .06 |
| Hemodialysis | 2 (29) | 5 (7) | .11 |
| Duration of diabetes, median (IQR), y | 7 (1-11) | 9 (1-13) | .84 |
| HbA1c, mean (SD), % | |||
| Baseline | 7.3 (1.8) | 7.2 (1.4) | .92 |
| 1-y follow-up | 6.9 (0.8) | 6.9 (1.1) | .98 |
| Insulin | 3 (43) | 9 (12) | .06 |
| Statin use | 6 (86) | 71 (96) | .31 |
| DAPT | 7 (100) | 73 (99) | >.99 |
| P2Y12 inhibitor use | 7 (100) | 71 (96) | >.99 |
| Lesion characteristics | |||
| No. of lesions | 15 | 111 | |
| Target vessel | |||
| RCA | 6 (40) | 30 (27) | .59 |
| LAD | 6 (40) | 56 (51) | |
| LCX | 3 (20) | 25 (23) | |
| ACC/AHA type B2/C | 9 (60) | 96 (87) | .02 |
| Bifurcation lesion | 8 (53) | 47 (42) | .58 |
| DES typeb | |||
| XIENCE | 8 (53) | 76 (69) | .008 |
| SYNERGY | 0 (0) | 14 (13) | |
| Resolute | 1 (7) | 9 (8) | |
| Endeavor | 5 (33) | 4 (4) | |
| Nobori | 1 (7) | 4 (4) | |
| Ultimaster | 0 (0) | 4 (4) | |
| Stent | |||
| Diameter, mean (SD), mm | 2.88 (0.36) | 3.05 (0.42) | .14 |
| Length, median (IQR), mm | 18.0 (15.0-23.0) | 23.0 (16.0-30.0) | .07 |
| QCA data, mean (SD) | |||
| Lesion length, mm | 20.1 (12.8) | 20.0 (9.6) | .99 |
| Reference diameter, mm | 2.63 (0.62) | 2.76 (0.60) | .44 |
| Pre | |||
| MLD, mm | 0.76 (0.48) | 0.92 (0.46) | .24 |
| %DS, % | 69.8 (17.4) | 72.9 (19.0) | .58 |
| Post | |||
| MLD, mm | 2.61 (0.54) | 2.61 (0.46) | .99 |
| %DS, % | 3.9 (7.7) | 8.2 (10.4) | .12 |
| Follow-up | |||
| MLD, mm | 1.41 (0.87) | 2.28 (0.68) | <.001 |
| %DS, median (IQR), % | 31.0 (10.0-82.0) | 13.0 (8.0-21.0) | .02 |
| Duration to follow-up CAG, median (IQR), mo | 10.1 (6.6-13.2) | 9.1 (7.0-11.0) | .39 |
| Vascular failure | |||
| ISR | 7 (47) | 10 (9) | <.001 |
| TLR | 5 (33) | 7 (6) | .006 |
| Restenosis morphology | |||
| Diffuse or occlusive type | 7 (100) | 2 (20) | .003 |
Abbreviations: ACC/AHA, American College of Cardiology/American Heart Association; BMI, body mass index; BMIPP, 123I-β-methyl iodophenyl-pentadecanoic acid; CAG, coronary angiography; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; DS, diameter stenosis; HbA1c, hemoglobin A1c; IQR, interquartile range; ISR, in-stent restenosis; LAD, left anterior descending artery; LCX, left circumflex artery; MI, myocardial infarction; MLD, minimal lumen diameter; QCA, quantitative coronary angiography; RCA, right coronary artery; TGCV, triglyceride deposit cardiomyovasculopathy; TLR, target lesion revascularization.
Values are written as No. (%) unless otherwise specified.
Manufacturers of the DESs are as follows: XIENCE (Abbott Vascular), SYNERGY (Boston Scientific), Resolute (Medtronic), Endeavor (Medtronic), Nobori (Terumo Corporation), Ultimaster (Terumo Corporation).